Drug Type Monoclonal antibody |
Synonyms NAV 140, NAV140 |
Target |
Action inhibitors |
Mechanism OX40L inhibitors(Tumor necrosis factor ligand superfamily member 4 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Immune System Diseases | Preclinical | United States | 01 Apr 2025 |






